This sixth podcast program, Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities, features an interview with Professor McInnes. He discusses the current state of knowledge in rheumatoid arthritis and directions for discovery in coming years.

Biologic Therapy In Rheumatoid Arthritis

Episode 6: Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities

This fifth podcast titled Progress and Prognosis: Evaluating Patients’ Responses to Biologic Therapy features a telephone interview with Professor Schett. He discusses differences among the anti-TNF agents in the treatment of rheumatoid arthritis.

Episode 5: Progress and Prognosis: Evaluating Patients' Responses to Biologic Therapy

Professor VonVollenhoven discusses factors which distinguish individual responses by patients with rheumatoid arthritis to various anti-TNF agents. He describes observations of radiologic and clinical progression of illness in subgroups of patients and provides an overview of considerations in choosing one pharmacologic agent over another. Professor VonVollenhoven also discusses recent research on the role of biologic markers for RA.

Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

Contemporary research shows that the early diagnosis and treatment of RA can offer patients the possibility of achieving remission. The goal for any patient with early RA should be to achieve remission. If a patient does not already have joint damage, the goal should be a normal acute-phase response and no swollen joints as soon as possible.

Episode 3: Anti-TNF Treatment: Focus on early Rheumatoid Arthritis. Featuring an interview with Professor Paul Emery

Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination therapy of a TNF-alpha agent and methotrexate results in highly significant improvement in arthritic symptoms and signs.

Episode 2: Establishing the Evidence: Clinical Trials with TNF Inhibitors

Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini utilized two new technologies -- protein sequencing and cDNA protein coding -- to investigate half a dozen cytokines that appeared to mediate the pathogenesis of connective tissue diseases. One of them, TNF-alpha, proved to play a pivotal role in the cascading interaction of cytokines. When antibody against TNF-alpha was produced, a new field of biologic therapy in the management of rheumatic diseases was born. In this interview, Professor Sir Maini describes the scientific discovery that earned him the title "Father of Translational Research." Listen to him describe this historic exploration in his own words. The podcast also features: Inflammation is Hallmark of Coronary Disease in RA

Episode 1: TNF-Alpha: Concept to Proof of Concept

Biologic Therapy in Rheumatoid Arthritis: Pioneers in Research, is a monthly series of podcasts featuring interviews with today's giants in rheumatology sponsored by Schering-Plough Corporation. In this series brought to you by Rheumatology News International, you will hear some of the greatest scientists in rheumatology describe the exploration of what was then uncharted medical territory. Their words will bring alive the journey of discovery that placed them in the annals of history's great medical investigators.

hubhopper

Biologic Therapy In Rheumatoid Arthritis

hubhopper